Aikai Biotech

Aikai Biotech (艾凯生物 / 艾凯利元) is a Suzhou-based biotech company developing next-generation universal off-the-shelf cell therapies using iPSC (induced pluripotent stem cell) technology . Founded in March 2021, the company raised over 200 million RMB in its Series A+ round in early 2022, drawing interest from investors including Westlake Innovation Investment and Lianxin Capital . 5Y Capital, which joined as an investor, has cited the "huge potential of iPSC technology in tumor immunotherapy and regenerative medicine" as the rationale for its backing . The company was notable for completing three funding rounds within its first year of operation .